A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Conditions

• Immunoglobulin Light Chain (AL) Amyloidosis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• ABBV-383 (Etentamig) — DRUG
  Intravenous Infusion

Study Details

Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by clonal bone marrow plasma cells. This is a study to determine adverse events and change in disease activity in adult participants with AL amyloidosis treated with ABBV-383. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of AL amyloidosis. This study in broken into 2 parts (dose escalation and dose expansion) with 4 arms. During dose escalation (arms 1-3) participants will receive 1 of 3 doses of ABBV-383 to determine the part 2 dose. After completion of the dose escalation portion of the study, the dose expansion (part 2) portion of the study will begin. One arm (arm 4) will begin and participants will receive a dose determined during the dose escalation portion (part 1). Around 76 adult participants with relapsed/refractory AL amyloidosis will be enrolled at approximately 25 sites across the world. Participants will receive Etentamig (ABBV-383) as an infusion into the vein for up to approximately 2 year study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Key Dates

Start date

Apr 1, 2024

Status verified

May 2026

Primary completion

Feb 29, 2028

Completion

Aug 31, 2031

Study Design

Enrollment

76 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Dose Escalation: ABBV-383 (etentamig) Dose A
  Participants will receive ABBV-383 (etentamig) dose A during the approximately 2 year study duration.
• Experimental: Dose Escalation: ABBV-383 (etentamig) Dose B
  Participants will receive ABBV-383 (etentamig) dose B during the approximately 2 year study duration.
• Experimental: Dose Escalation: ABBV-383 (etentamig) Dose C
  Participants will receive ABBV-383 (etentamig) dose C during the approximately 2 year study duration.
• Experimental: Dose Expansion: ABBV-383 (etentamig)
  Participants will receive ABBV-383 (etentamig) expansion dose B during the approximately 2 year study duration.

Primary Outcome Measure

Dose Escalation Only: Number of Participants with Dose-Limiting Toxicities (DLT) [ Time Frame: Up to 28 Days ]

Central Contacts

• ABBVIE CALL CENTER
  844-663-3742
  [email protected]

Locations (12)

Find similar trials in Miami, FL